Expert Interview
Discussing 89bio’s pegozafermin in severe hypertriglyceridemia, following Phase 2 Data Results
Ticker(s): ETNBInstitution: Utah Lipid Center
- President and Director of the Utah Lipid Center and past president of the American Board of Clinical Lipidology.
- Treats 50 patients with hypertriglyceridemia (SHTG)
- Responsible for writing guidelines for the American Heart Association and the American Association of Clinical Endocrinology; has co-authored over 160 scientific articles, reviews, book chapters.
Please describe your clinical practice. How many patients with SHTG do you see on a yearly basis? Could you talk to us about the standard of care?
How well do patients respond to treatment with fenofibrate and omega-3 fatty acid therapy or Epanova, and how does it stand up to new and emerging treatment options? How critical is the need for new drugs?
Can you talk to us about the mechanism of action of glycoPEGylated analogs of fibroblast growth factor 21 (FGF21) ? What are the benefits specific to pegozafermin, how important is the extended half-life ?
How often do patients develop pancreatitis? What approach works best to prevent that from happening?
Added By: catalin_adminCould you please share your thoughts on the Phase 2 results, where 88% of treated patients vs. 0% of placebo patients achieved a ≥30% reduction in liver fat from baseline and 24% of treated patients vs. 0% of placebo patients achieved normalized levels of liver fat at week.https://ir.89bio.com/news-releases/news-release-details/89bio-presents-positive-results-entrigue-pha...
Added By: catalin_adminPlease discuss the findings showing non-HDL-C reductions in both apo-B subtypes, apoB48 and apoB100; can you comment on pegozafermin reducing atherogenic lipoproteins and chylomicrons?
How likely would you be to switch patients to pegozafermin?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
